This action begins with a decrease in plasma volume and increased hemoconcentration; however, it has been demonstrated that the improvement in anemia among patients with diabetes treated with SGLT2 inhibitors goes beyond the reduction of plasma volume [2]. This evidence concerns the gene SLC5A2 and diabetes mellitus.